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margins and lobulated contours, distributed bilaterally (BreastIntroduction
The neoplasm of plasma cells is a group of diseases encom-
passing from monoclonal gammopathy of undetermined
signiﬁcance (MGUS) to multiple myeloma (MM).1
Conglomerates of monoclonal plasma cells are called plas-
macytomas and are included in this group.2 They can occur
in isolation or associated with MM,  with the most common
location being bone tissue.3
The existence of extramedullary plasmacytomas has also
been described. Most commonly, they affect the head, neck
and subcutaneous tissues, especially of the upper respiratory
tract.4
They are present in 7–19% of patients at the time MM is
diagnosed and in another 6–20% during the course of the
disease.5
Breast plasmacytoma is a rare condition. In 2006, Taylor
2et al., described 43 cases in the literature. Diagnosis is made
by pathology however imaging can further aid the diagnosis
of the disease. Ultrasound and mammographic aspects have
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magnetic resonance imaging.2–4 A case of MM  with mammary
gland involvement at diagnosis is described herein.
Case  report
A 52-year-old, Black female patient was admitted to hos-
pital with asthenia. She had suffered 10 kg of weight loss,
pain in the thoracic region and vomiting. The physical exam-
ination showed pain on palpating the chest and bilateral
breast lumps. Initial tests showed bicytopenia (anemia and
thrombocytopenia), renal dysfunction, and hypercalcemia.
First, the symptomatic hypercalcemia was controlled and,
subsequently, an investigation into the etiology was carried
out, with mammary  neoplasm being the initial hypothe-
sis. Mammography showed hyperdense nodules, with regular4021020 São Paulo, SP, Brazil.
Imaging-Reporting and Data System – BI-RADS 0), whereas
ultrasonography showed multiple solid oval-shaped nodules
with lobulated contours and with vascularization by color
 e Terapia Celular. Published by Elsevier Editora Ltda. This is an
mons.org/licenses/by-nc-nd/4.0/).
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Figure 1 – (A and B) Mammography: hyperdense and lobulated nodules with circumscribed margins; (C) extra-axial
expansive lesion compatible with plasmocytoma in the right frontal convexity (arrow) with pachymeningeal impregnation
(arrowhead), demonstrating central nervous system involvement; (D) spectroscopy of the same patient showing an
increased glutamine–glutamate complex (arrow) resulting from elevated central nervous system ammonia.
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hoppler (Figure 1). A core biopsy was performed. Test results,
owever, ruled out primary breast cancer while showing
reast plasmacytoma, with lambda chain restriction, plasma
ell ratio of 95%, CD138+ and negative for CD56 (Figure 2).
ther tests conducted to conﬁrm MM were positive. Protein
lectrophoresis identiﬁed monoclonal components (5.34 g/dL),
mmunoﬁxation identiﬁed IgA/Lambda and bone marrow
iopsy showed bone marrow plasmacytosis 90%, CD138+, and
ambda+ (Figure 2). Hence, a diagnosis of IgA/lambda MM
ith extramedullary plasmacytoma located in the breast was
eached, with an international staging system score of III and
urie Salmon (DS) stage of IIIB.
The patient underwent induction chemotherapy with
he administration of the CTD regimen (cyclophosphamide,
halidomide, and dexamethasone). After three cycles, her clin-
cal condition worsened with altered level of consciousness,
eizures, and disease progression with new plasmacy-
omas (sternum and central nervous system − CNS) and
yperammonemia being observed. This metabolic changewas established by measuring the serum ammonia level
(93 mol/L; normal value up to 32 mol/L) and conﬁrmed
by proton magnetic resonance spectroscopy (PMRS), which
showed a glutamine/glutamate peak and reduced choline and
myo-inositol (Figure 1).
The chemotherapy regimen was then changed to a
combination of dexamethasone, thalidomide, doxorubicin,
cisplatin, cyclophosphamide, and etoposide (DT-PACE). After
three cycles of this chemotherapeutic regimen, the mono-
colonal component reduced completely and there was a
reduction in the extramedullary plasmacytomas (breast, ster-
num, and CNS). Treatment then proceeded with high-dose
melphalan and rescue with autologous hematopoietic progen-
itor stem cell transplantation and subsequent radiotherapy
against the sternal plasmocytoma.Disease progression was observed 30 days after the trans-
plant with meningeal inﬁltration, with the liquor having
88% of plasma cells positive for CD38, CD56, CD117, CD138,
and CD200. The patient underwent palliative treatment with
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Figure 2 – (A) Breast and (B) bone marrow biopsies, both with hematoxylin and eosin (HE) staining characterized by
inﬁltration of plasma cells; Breast biopsy immunochemistry with (C) lambda restriction and (D) CD138+ immunoexpression.intrathecal chemotherapy (methotrexate, cytarabine, and
dexamethasone).
She evolved to death ten months after diagnosis, with
multiple extramedullary plasmacytomas (breast, sternum,
CNS, subcutaneous tissue) and absence of any monoclonal
component.
Discussion
Extramedullary plasmacytomas of the breast are rare; they
have been found at diagnosis in only 14% of cases. Most (75%)
plasmacytomas of the breast occur during relapse of MM.2
The epidemiological characteristics of the case described
herein are consistent with the data in the literature, regarding
gender and age. Most breast plasmocytomas occur in women
with a mean age of 53 years at diagnosis, but predominantly
unilateral.2,3
The mammographic results of this patient are in agree-
ment with the ﬁndings reported in the literature as
well-deﬁned masses with irregular margins. On the other
hand, the ultrasonographic pattern described by authors is
heterogeneous, with hyperechoic, hypoechoic, or anechoic
lesions being reported.3The prognosis of patients with extramedullary plasma-
cytoma is variable. Solitary plasmacytomas have a good
prognosis (radiotherapy and surgery are curative treatment
options) and less than 30% of cases develop MM or other plas-
macytomas, whereas the disease progresses with unfavorable
outcomes in patients with MM  and extramedullary primary or
secondary plasmacytomas, as in this case.5
Progression of the disease was observed in the current case
with new extramedullary plasmacytomas despite of the CTD
regimen. Using PMRS and determination of serum ammo-
nia levels, hyperammonemic encephalopathy was also found.
This condition together with MM and without liver disease is
rare (3.8%). Nevertheless, it should be considered in patients
with altered levels of consciousness, as observed in this
patient.6,7
Hyperammonemia was not considered as the only single
factor for the altered mental status, but part of a complex
scenario, which included hyperviscosity of the blood, CNS
inﬁltration, and hypercalcemia.
This encephalopathy is caused by the production of ammo-
nia at critical levels by the plasma cells themselves, thereby
exceeding the depuration capacity of hepatocytes.8
In the systematic review by Pham et al.,6 hyperammone-
mic  encephalopathy was more  commonly related to myeloma
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ubtypes IgA and IgG, advanced stages of the disease, and CNS
nﬁltration, which leads to a worse prognosis with higher rates
f hospitalization and mortality.9,10
Considering the progression and aggressiveness of the
isease, the choice was to modify treatment to the DT-PACE
egimen.11 Bladè et al.12 found that extramedullary dis-
ase appears to be more  properly treated with intensive
hemotherapy regimens, including new agents such as
enalidomide and pomalidomide, compared to traditional
herapies for MM;  however, this option is not clearly described
n the literature yet.
Extramedullary disease, whether the patient has plasma-
ytomas of the bone or not, may be the most important clinical
nding in the course of MM,  as in this case. The biological
echanisms underlying this occurrence have not been prop-
rly established, but a series of events are postulated. These
ncluding decreased expression of adhesion molecules (CD44
nd CD56), increased angiogenesis, loss of cytokine receptors
esponsible for plasma cell homing [C-X-C chemokine recep-
or type 4 (CXCR4) and C-X-C motif chemokine 12 (CXCL12)]
nd bone marrow hypoxemia, causing these cells to migrate to
he periphery. Although the loss of CD56 expression facilitates
ematogenous or bone dissemination, its expression is para-
oxically associated with impairment of speciﬁc sites, such as
he CNS.13,14
The heterogeneity in CD56 marking could be duly
videnced in this case, where there was loss of CD56 expres-
ion in the plasmocytoma of the breast and, during the
atient’s progression, this marker was shown to be positive
hen immunophenotyping the liquor; this suggests the inﬂu-
nce of as yet unknown mechanisms and other factors.
Although cytogenetics assays were not carried out, this
oes not seem to be a ﬁnding capable of predicting out-
omes. Varga et al.,15 in a study of 117 patients, demonstrated
hat unfavorable cytogenetics results at diagnosis did not
etermine the occurrence of extramedullary disease or poor
rognosis.
The clinical characteristics and laboratory results of this
atient were already indicative of a poor prognosis with
ow chances of survival at diagnosis (ISS: III). Her progres-
ion with extramedullary plasmocytomas, probably due to
ematogenous dissemination, only corroborated the biolog-
cal complexity of the disease. The median survival time
eported for these cases is ten months in spite of the treatment
dministered, as was seen in this case.13,15onﬂict  of  interest
he authors declare no conﬂicts of interest. 1 6;3  8(2):166–169 169
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